Home Biotechnology mRNA Vaccines and Therapeutics Market Trends, Growth, & Share-2033

mRNA Vaccines and Therapeutics Market Size & Outlook, 2025-2033

mRNA Vaccines and Therapeutics Market Size, Share & Trends Analysis Report By Applications (COVID-19 mRNA vaccines, Non-COVID-19 mRNA vaccines), By mRNA type (COVID-19, Non-COVID-19) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRBI54284DR
Last Updated : Jun, 2025
Pages : 150
Author : Dhanashri Bhapakar
Format : PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global mRNA Vaccines and Therapeutics Market Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. COVID-19 mRNA vaccines
        1. By Value
        2. Commercialized Vaccines
          1. Commercialized Vaccines By Value
        3. Pipeline Vaccines
          1. Pipeline Vaccines By Value
      3. Non-COVID-19 mRNA vaccines
        1. By Value
        2. Oncology
          1. Oncology By Value
        3. Infectious Diseases
          1. Infectious Diseases By Value
        4. Other Diseases
          1. Other Diseases By Value
    3. By mRNA type
      1. Introduction
        1. mRNA type By Value
      2. COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA
          1. Self-Amplifying mRNA By Value
      3. Non-COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA)
          1. Self-Amplifying mRNA) By Value
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. COVID-19 mRNA vaccines
        1. By Value
        2. Commercialized Vaccines
          1. Commercialized Vaccines By Value
        3. Pipeline Vaccines
          1. Pipeline Vaccines By Value
      3. Non-COVID-19 mRNA vaccines
        1. By Value
        2. Oncology
          1. Oncology By Value
        3. Infectious Diseases
          1. Infectious Diseases By Value
        4. Other Diseases
          1. Other Diseases By Value
    3. By mRNA type
      1. Introduction
        1. mRNA type By Value
      2. COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA
          1. Self-Amplifying mRNA By Value
      3. Non-COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA)
          1. Self-Amplifying mRNA) By Value
    4. U.S.
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. COVID-19 mRNA vaccines
          1. By Value
          2. Commercialized Vaccines
            1. Commercialized Vaccines By Value
          3. Pipeline Vaccines
            1. Pipeline Vaccines By Value
        3. Non-COVID-19 mRNA vaccines
          1. By Value
          2. Oncology
            1. Oncology By Value
          3. Infectious Diseases
            1. Infectious Diseases By Value
          4. Other Diseases
            1. Other Diseases By Value
      2. By mRNA type
        1. Introduction
          1. mRNA type By Value
        2. COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA
            1. Self-Amplifying mRNA By Value
        3. Non-COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA)
            1. Self-Amplifying mRNA) By Value
    5. Canada
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. COVID-19 mRNA vaccines
        1. By Value
        2. Commercialized Vaccines
          1. Commercialized Vaccines By Value
        3. Pipeline Vaccines
          1. Pipeline Vaccines By Value
      3. Non-COVID-19 mRNA vaccines
        1. By Value
        2. Oncology
          1. Oncology By Value
        3. Infectious Diseases
          1. Infectious Diseases By Value
        4. Other Diseases
          1. Other Diseases By Value
    3. By mRNA type
      1. Introduction
        1. mRNA type By Value
      2. COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA
          1. Self-Amplifying mRNA By Value
      3. Non-COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA)
          1. Self-Amplifying mRNA) By Value
    4. U.K.
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. COVID-19 mRNA vaccines
          1. By Value
          2. Commercialized Vaccines
            1. Commercialized Vaccines By Value
          3. Pipeline Vaccines
            1. Pipeline Vaccines By Value
        3. Non-COVID-19 mRNA vaccines
          1. By Value
          2. Oncology
            1. Oncology By Value
          3. Infectious Diseases
            1. Infectious Diseases By Value
          4. Other Diseases
            1. Other Diseases By Value
      2. By mRNA type
        1. Introduction
          1. mRNA type By Value
        2. COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA
            1. Self-Amplifying mRNA By Value
        3. Non-COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA)
            1. Self-Amplifying mRNA) By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. COVID-19 mRNA vaccines
        1. By Value
        2. Commercialized Vaccines
          1. Commercialized Vaccines By Value
        3. Pipeline Vaccines
          1. Pipeline Vaccines By Value
      3. Non-COVID-19 mRNA vaccines
        1. By Value
        2. Oncology
          1. Oncology By Value
        3. Infectious Diseases
          1. Infectious Diseases By Value
        4. Other Diseases
          1. Other Diseases By Value
    3. By mRNA type
      1. Introduction
        1. mRNA type By Value
      2. COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA
          1. Self-Amplifying mRNA By Value
      3. Non-COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA)
          1. Self-Amplifying mRNA) By Value
    4. China
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. COVID-19 mRNA vaccines
          1. By Value
          2. Commercialized Vaccines
            1. Commercialized Vaccines By Value
          3. Pipeline Vaccines
            1. Pipeline Vaccines By Value
        3. Non-COVID-19 mRNA vaccines
          1. By Value
          2. Oncology
            1. Oncology By Value
          3. Infectious Diseases
            1. Infectious Diseases By Value
          4. Other Diseases
            1. Other Diseases By Value
      2. By mRNA type
        1. Introduction
          1. mRNA type By Value
        2. COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA
            1. Self-Amplifying mRNA By Value
        3. Non-COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA)
            1. Self-Amplifying mRNA) By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. COVID-19 mRNA vaccines
        1. By Value
        2. Commercialized Vaccines
          1. Commercialized Vaccines By Value
        3. Pipeline Vaccines
          1. Pipeline Vaccines By Value
      3. Non-COVID-19 mRNA vaccines
        1. By Value
        2. Oncology
          1. Oncology By Value
        3. Infectious Diseases
          1. Infectious Diseases By Value
        4. Other Diseases
          1. Other Diseases By Value
    3. By mRNA type
      1. Introduction
        1. mRNA type By Value
      2. COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA
          1. Self-Amplifying mRNA By Value
      3. Non-COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA)
          1. Self-Amplifying mRNA) By Value
    4. UAE
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. COVID-19 mRNA vaccines
          1. By Value
          2. Commercialized Vaccines
            1. Commercialized Vaccines By Value
          3. Pipeline Vaccines
            1. Pipeline Vaccines By Value
        3. Non-COVID-19 mRNA vaccines
          1. By Value
          2. Oncology
            1. Oncology By Value
          3. Infectious Diseases
            1. Infectious Diseases By Value
          4. Other Diseases
            1. Other Diseases By Value
      2. By mRNA type
        1. Introduction
          1. mRNA type By Value
        2. COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA
            1. Self-Amplifying mRNA By Value
        3. Non-COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA)
            1. Self-Amplifying mRNA) By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. COVID-19 mRNA vaccines
        1. By Value
        2. Commercialized Vaccines
          1. Commercialized Vaccines By Value
        3. Pipeline Vaccines
          1. Pipeline Vaccines By Value
      3. Non-COVID-19 mRNA vaccines
        1. By Value
        2. Oncology
          1. Oncology By Value
        3. Infectious Diseases
          1. Infectious Diseases By Value
        4. Other Diseases
          1. Other Diseases By Value
    3. By mRNA type
      1. Introduction
        1. mRNA type By Value
      2. COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA
          1. Self-Amplifying mRNA By Value
      3. Non-COVID-19
        1. By Value
        2. Nucleoside-Modified mRNA (modRNA)
          1. Nucleoside-Modified mRNA (modRNA) By Value
        3. Unmodified mRNA
          1. Unmodified mRNA By Value
        4. Self-Amplifying mRNA)
          1. Self-Amplifying mRNA) By Value
    4. Brazil
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. COVID-19 mRNA vaccines
          1. By Value
          2. Commercialized Vaccines
            1. Commercialized Vaccines By Value
          3. Pipeline Vaccines
            1. Pipeline Vaccines By Value
        3. Non-COVID-19 mRNA vaccines
          1. By Value
          2. Oncology
            1. Oncology By Value
          3. Infectious Diseases
            1. Infectious Diseases By Value
          4. Other Diseases
            1. Other Diseases By Value
      2. By mRNA type
        1. Introduction
          1. mRNA type By Value
        2. COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA
            1. Self-Amplifying mRNA By Value
        3. Non-COVID-19
          1. By Value
          2. Nucleoside-Modified mRNA (modRNA)
            1. Nucleoside-Modified mRNA (modRNA) By Value
          3. Unmodified mRNA
            1. Unmodified mRNA By Value
          4. Self-Amplifying mRNA)
            1. Self-Amplifying mRNA) By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. mRNA Vaccines and Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Arcturus Therapeutics Holdings Inc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. BioNTech SE
    3. Daiichi Sankyo Company
    4. CureVac N.V
    5. Limited
    6. ethris GmbH
    7. GlaxoSmithKline plc
    8. Gennova Biopharmaceuticals Ltd
    9. Genova Biopharmaceuticals Ltd
    10. Moderna Inc
    11. Panthera Therapeutics GmbH
    12. Providence Therapeutics
    13. Silence Therapeutics
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Available for purchase with detailed segment data, forecasts, and regional insights.

Get This Report

Download Free Sample

Note: Please ensure you provide an active email address as we will be sending sample details via email.
The button will be active once the above form is filled

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on :

Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.